Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Mohty

Showing results (91-100 of 176) with videos related to

Pageof 18
Sort By:
Bone Marrow Transplantation|December 8, 2015
Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institutionE Brissot, F Rialland, X Cahu, et al.
Bone Marrow Transplantation|March 12, 2014
Allo-SCT for  Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)X Cahu, P Chevallier, A Clavert, et al.
Bone Marrow Transplantation|January 10, 2024
Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL-a report from the EBMT registryA Sadowska-Klasa, J M Zaucha, M Labopin, et al.
Bone Marrow Transplantation|September 15, 2015
Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMTT Ruutu, L C de Wreede, A van Biezen, et al.
Bone Marrow Transplantation|July 1, 2014
Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMTM A Kharfan-Dabaja, M Labopin, A Bazarbachi, et al.
Bone Marrow Transplantation|July 9, 2009
Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cellsM Lioznov, J El-Cheikh, F Hoffmann, et al.
Leukemia|July 24, 2012
Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblingsN Kröger, T Zabelina, L de Wreede, et al.
Bone Marrow Transplantation|September 10, 2005
Early administration of recombinant erythropoietin improves hemoglobin recovery after reduced intensity conditioned allogeneic stem cell transplantationV Ivanov, C Faucher, M Mohty, et al.
Bone Marrow Transplantation|December 5, 2012
Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMTR Martino, L de Wreede, M Fiocco, et al.
Bone Marrow Transplantation|March 14, 2017
Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey reportJ R Passweg, H Baldomero, P Bader, et al.
Pageof 18

Showing results (91-100 of 176) with videos related to

Sort By:
Pageof 18
Bone Marrow Transplantation|December 8, 2015
Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institutionE Brissot, F Rialland, X Cahu, et al.
Bone Marrow Transplantation|March 12, 2014
Allo-SCT for  Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)X Cahu, P Chevallier, A Clavert, et al.
Bone Marrow Transplantation|January 10, 2024
Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL-a report from the EBMT registryA Sadowska-Klasa, J M Zaucha, M Labopin, et al.
Bone Marrow Transplantation|September 15, 2015
Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMTT Ruutu, L C de Wreede, A van Biezen, et al.
Bone Marrow Transplantation|July 1, 2014
Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMTM A Kharfan-Dabaja, M Labopin, A Bazarbachi, et al.
Bone Marrow Transplantation|July 9, 2009
Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cellsM Lioznov, J El-Cheikh, F Hoffmann, et al.
Leukemia|July 24, 2012
Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblingsN Kröger, T Zabelina, L de Wreede, et al.
Bone Marrow Transplantation|September 10, 2005
Early administration of recombinant erythropoietin improves hemoglobin recovery after reduced intensity conditioned allogeneic stem cell transplantationV Ivanov, C Faucher, M Mohty, et al.
Bone Marrow Transplantation|December 5, 2012
Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMTR Martino, L de Wreede, M Fiocco, et al.
Bone Marrow Transplantation|March 14, 2017
Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey reportJ R Passweg, H Baldomero, P Bader, et al.
Pageof 18